Oric Pharmaceuticals Inc expected to post a loss of 46 cents a share - Earnings Preview

ORIC Pharmaceuticals

04/11/2023 03:04

* Oric Pharmaceuticals Inc  ORIC.OQ   ORIC.O  is expected
to show
no change in quarterly revenue when it reports  results 
    * 
    * ​Refinitiv's mean analyst estimate for Oric
Pharmaceuticals Inc
is for a loss of 46 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 8 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Oric
Pharmaceuticals Inc is $15​, above​ its last closing price
of $7.08. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.57       -0.57      -0.50     Beat    12.1
 Mar. 31 2023  -0.54       -0.54      -0.53     Beat    1.9
 Dec. 31 2022  -0.51       -0.54      -0.52     Beat    3​
 Sep. 30 2022  -0.55       -0.55      -0.63     Missed  -13.8
 ​​Jun.        -0.61       -0.60      -0.51     Beat    15
 30 2022                                                
 Mar. 31 2022  -0.56       -0.57      -0.59     Missed  -3.8​
 Dec. 31 2021  -0.49       -0.57      -0.58     Missed  -2.6
 Sep. 30 2021  -0.57       -0.58      -0.47     Beat    19.3
 This summary was machine generated November 4 at 03:04 GMT.  All
figures in US dollars  unless otherwise stated